Products

Three insulin analogues: rapid-acting, pre-mixed and long-acting.

Portfolio overview

Our insulin analogues.

Rapid-acting

Insulin aspart

Approved; marketed since October 2023

Pre-mixed

Insulin aspart mix

Approved September 2025

Long-acting

Insulin glargine

Phase III completed; approved by SEC

Product information on these pages is intended for healthcare professionals.

Product

Insulin aspart

Class
Rapid-acting insulin analogue.
Reference medicine
Innovator’s insulin aspart.
Presentations
Cartridges, vials and prefilled disposable pens.
Status
Approved in India; marketed since October 2023 by USV Private Limited as InsuQuick™. European filing planned for 2027.
Product

Insulin aspart mix

Class
Pre-mixed insulin analogue (30% soluble insulin aspart, 70% insulin aspart protamine).
Reference medicine
Innovator’s insulin aspart mix 30.
Status
Approved in India in September 2025. Launch in India planned.
Product

Insulin glargine

Class
Long-acting basal insulin analogue.
Reference medicine
Innovator’s insulin glargine.
Status
Phase III completed; approved by the Subject Expert Committee (SEC).
Pipeline

Beyond our lead products.

These products span prandial, biphasic, and basal insulin segments, enabling portfolio coverage across multiple treatment regimens in diabetes care. Beyond the lead products, BioGenomics has developed a broader insulin analogue pipeline, leveraging a common platform technology and accumulated process knowledge.

Approved and launched

Insulin aspart

Rapid-acting insulin analogue

Reference: innovator’s insulin aspart

Strong physician familiarity; limited biosimilar competition in several markets.

Approved, awaiting launch

Insulin aspart mix

Pre-mixed insulin analogue

Reference: innovator’s insulin aspart mix 30

Strong physician familiarity; limited biosimilar competition in several markets.

Approved by SEC

Insulin glargine

Basal insulin

Reference: innovator’s insulin glargine

Established basal insulin with strong physician adoption.

Products in pipeline

Faster-acting insulin aspart

Ultra-fast insulin analogue

Ultra-rapid insulin segment with lean competition and a straightforward development pathway.

Insulin icodec

Ultra-long insulin analogue

Next-generation once-weekly basal insulin.

Insulin icodec + GLP-1 analogue

Ultra-long insulin analogue + GLP-1 analogue

Next-generation once-weekly basal insulin combined with semaglutide.

Insulin glargine 300 U/mL

Basal insulin (high concentration)

Growing next-generation basal insulin segment with limited biosimilar competition.

Insulin degludec + insulin aspart

Ultra-long insulin analogue + rapid-acting

Long-acting + fast-acting combination.

We have also developed over 15 biotech non-therapeutic enzymes. Our recombinant enzymes, such as recombinant trypsin, carboxypeptidase B (CPB) and enterokinase, are manufactured at our plant in Puducherry and sold commercially to global customers. They also support our core business, including in-house analytical characterisation, quality-control testing and process-development services. More on our enzymes